TPTX News and Press, Turning Point Therapeutics Inc. From 09/30/19

The FDA clears Turning Point Therapeutics' (NASDAQ: TPTX ) IND for TPX-0046, a novel therapy targeting solid tumors with abnormal RET genes by inhibiting RET and SRC kinases. More news on: Turning Point Therapeutics, Inc., Healthcare stocks news, Read more ...

SAN DIEGO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug applic...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

Aurinia Pharmaceuticals (NASDAQ: AUPH ) initiated with Outperform rating and $14 (141% upside) price target at Oppenheimer. Shares up  4%  premarket. More news on: Aurinia Pharmaceuticals Inc., Homology Medicines, Inc., IDEAYA Biosciences, Inc., Healthcare stocks news, Stocks on ...

Domo (NASDAQ: DOMO ) -35%  on Q2 results and analyst downgrade . More news on: Domo, Inc., Avid Bioservices, Inc., Eltek Ltd., Stocks on the move, Read more ...

Turning Point Therapeutics (NASDAQ: TPTX ) has priced its public offering of 4.5M common shares at $45.00/share, for expected gross proceeds of $202.5M. More news on: Turning Point Therapeutics, Inc., Read more ...

SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the pricing of its public offering of 4,500,000 shares of common stock at a price to the public...

SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced today it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (...

In TKI-naïve ROS1+ NSCLC Patients, Overall Response Rate by Blinded Review Improved to 91 Percent; Median Duration of Response Not Yet Mature with 20.1 months of Median Follow-Up Improved Results in Heavily Pretreated ROS1+ NSCLC Patients, with First Confirmed Responses in P...